ストックスクリーナーアプリを入手
0.3612
11.39%
-0.0338
前日終値:
$0.395
開ける：
$0.371
24時間の取引高:
166.98K
Relative Volume:
0.51
時価総額：
$8.22M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-21.35%
1か月 パフォーマンス:
-33.96%
6か月 パフォーマンス:
-50.56%
1年 パフォーマンス:
-77.27%
1日の値動き範囲:
$0.33
$0.38
1週間の範囲:
$0.33
$0.4661
52週間の値動き範囲:
$0.3176
$2.58
Cellyan Biotechnology Co Ltd Stock (HKPD) Company Profile
Compare HKPD vs MCK, COR, CAH, HSIC, AHG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HKPD
Cellyan Biotechnology Co Ltd
|
0.35 | 9.28M | 0 | 0 | 0 | 0.00 |
MCK
Mckesson Corp
|
745.44 | 87.88B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
271.00 | 52.89B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
222.51 | 51.94B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
78.86 | 9.10B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.25 | 1.15B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cellyan Biotechnology Co Ltd (HKPD) 最新ニュース
Cellyan Biotech (HKPD) Slides 7.6%, Testing Key Support at $0.39Channel Projection - newsline.com
Cellyan Biotechnology (NASDAQ: HKPD) files $200M shelf to sell shares, debt - Stock Titan
Cellyan Biotechnology (HKPD) director CHAN Kam Leung files initial Form 3 - Stock Titan
[Form 3] Cellyan Biotechnology Co., Ltd Initial Statement of Beneficial Ownership - Stock Titan
Cellyan Biotechnology (HKPD) Chief Strategy Officer listed with no Form 3 transactions - Stock Titan
12 Industrials Stocks Moving In Tuesday's After-Market Session - Benzinga
Cellyan Biotechnology (HKPD) CFO Liu Shu files initial ownership Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Zhou Mike Yao files initial Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Wu Jingyan submits initial SEC Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) CEO and director files Form 3 with no share transactions - Stock Titan
Cellyan Biotechnology (HKPD) Slumps 7.83%: Key Support at $0.50 Under PressureFibonacci Fan - The Legal Advocate
Cellyan Biotechnology (HKPD) Holds Steady Near Support After Marginal GainsAdvance Decline Volume - The Legal Advocate
Cellyan Biotechnology (HKPD) Drops 3.6% as Shares Approach Critical $0.50 SupportButterfly Setup - The Legal Advocate
Cellyan Biotechnology Faces Resistance at $0.57 After Recent DeclineTotal Put Call - newsline.com
11 Industrials Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Cellyan (HKPD) quarterly earnings report shows no revenue, EPS data available amid biotechnology sector headwinds.Shared Buy Zones - Newser
What net volume Cellyan (HKPD)? (Smart Money Outflows) 2026-04-29Buy Signals - newser.com
What leverage Cellyan (HKPD)? | HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressSocial Trading Insights - newser.com
HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressPretax Income Report - The Legal Advocate
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
HKPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HKPD (Cellyan) posts 21.7 percent Q2 2025 revenue growth, shares drop 6.58 percent amid negative earnings.Dividend Increase Stocks - The Legal Advocate
Cellyan (HKPD) Stock: Is It Ready for Entry (Institutional Demand) 2026-04-18Index Investing - Cổng thông tin điện tử tỉnh Lào Cai
HKPD Technical Analysis & ETF Price Forecast - Intellectia AI
[EFFECT] Cellyan Biotechnology Co., Ltd SEC Filing - Stock Titan
HKPD Stock Analysis: Cellyan Biotechnology Co. Ltd gains 1.59% to trade at 0.57 dollar - newsline.com
12 Industrials Stocks Moving In Monday's Intraday Session - Benzinga
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), the selling shareholders of Cellyan Biotechnology Co Ltd may sell up to 12.5 million Class A ordinary shares from time to time in the future. - Bitget
12.5M shares for resale — Cellyan Biotechnology (NASDAQ: HKPD) - stocktitan.net
Cellyan Biotechnology (HKPD) completes $6.5M private unit financing - Stock Titan
If You Invested $1,000 in Cellyan Biotechnology Co Ltd (HKPD) - Stock Titan
Cellyan Biotechnology Reports Lower Revenue and Profit in Latest Interim Results - TipRanks
Cellyan Biotechnology (HKPD) interim revenue and profit drop sharply in 2025 - Stock Titan
Cellyan Biotechnology Co., Ltd Reports Earnings Results for the Half Year Ended September 30, 2025 - marketscreener.com
HKPD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PETS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cellyan Biotechnology receives Nasdaq bid price deficiency notice - MSN
Cellyan Biotechnology boosts share capital and completes name change after December AGM - MSN
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - The Manila Times
Cellyan Biotechnology receives Nasdaq minimum bid price deficiency notice - Investing.com
Cellyan Biotechnology Hit With Nasdaq Bid-Price Deficiency Notice, Shares Remain Listed - TipRanks
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cellyan Biotechnology Co Ltd (NASDAQ:HKPD) - intelligentinvestor.com.au
Cellyan Biotechnology Co Ltd (NASDAQ: HKPD)Share Price - intelligentinvestor.com.au
Clinical Trial Supplies Company Evaluation Report 2025: Market Led by Thermo Fisher Scientific, Sharp Services, and Parexel Through End-to-End Capabilities Span Packaging, Logistics, Trial ManagementResearchAndMarkets.com - FinancialContent
Cellyan Biotechnology Co., Ltd: Dividend historical data and projections - MarketScreener
HKPD: Static price chart | Cellyan Biotechnology Co., Ltd | KYG6365B1041 - MarketScreener
Cellyan Biotechnology Co., Ltd: Shareholders Board Members Managers and Company Profile | KYG6365B1041 - MarketScreener
There was once a stone that lay deep in the heart of a flowing river.Stock Buy Signals & Get The Analyst Consensus With One Click - bollywoodhelpline.com
Technical Charts Suggest Momentum Shift in Silicon Rental Solutions LimitedMoving Average Crossovers & Free Get High Impact Recommendations - bollywoodhelpline.com
Hawa Engineers Limited Nearing Breakout Level After BounceMid Cap Growth Trends & Plan Your Future With Strategic Investing - bollywoodhelpline.com
Cellyan Biotechnology Co Ltd (HKPD) 財務データ
Cellyan Biotechnology Co Ltd (HKPD) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
4.44%
0.00%
大文字化:
|
ボリューム (24 時間):